With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

Armed with lab equipment and two months of food and clothes, around 60 researchers boarded the RSV Nuyina icebreaker ship for ...

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study.

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Meeting, held April 24–28 in Honolulu, reveals that young children with chronic conditions are more likely to be hospitalized ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

The Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory ...

May is Lupus Awareness Month, and the Lupus Foundation of Arkansas is planning some events they hope you will attend.